Search hospitals > Michigan > Brighton
University of Michigan - Brighton Center for Specialty Care
Claim this profileBrighton, Michigan 48116
Global Leader in Cancer
Conducts research for Squamous Cell Carcinoma
Conducts research for Adenocarcinoma
Conducts research for Tumors
Conducts research for Bladder Cancer
24 reported clinical trials
13 medical researchers
Summary
University of Michigan - Brighton Center for Specialty Care is a medical facility located in Brighton, Michigan. This center is recognized for care of Cancer, Squamous Cell Carcinoma, Adenocarcinoma, Tumors, Bladder Cancer and other specialties. University of Michigan - Brighton Center for Specialty Care is involved with conducting 24 clinical trials across 158 conditions. There are 13 research doctors associated with this hospital, such as Francis P. Worden, Zachery R. Reichert, Jean H. Siedel, and Mark M. Zalupski.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
p16 negative
2Squamous Cell Carcinoma
p16 negative
Stage II
Stage III
Top PIs
Francis P. WordenUniversity of Michigan5 years of reported clinical research
Studies Cancer
Studies Thyroid Cancer
13 reported clinical trials
23 drugs studied
Zachery R. ReichertUniversity of Michigan Comprehensive Cancer Center5 years of reported clinical research
Studies Prostate Cancer
Studies Cancer
7 reported clinical trials
15 drugs studied
Jean H. SiedelUniversity of Michigan Comprehensive Cancer Center1 year of reported clinical research
Studies Adenocarcinoma
Studies Serous Cystadenocarcinoma
8 reported clinical trials
22 drugs studied
Mark M. ZalupskiUniversity of Michigan Comprehensive Cancer Center7 years of reported clinical research
Studies Gastrointestinal Tumors
Studies Adenocarcinoma
5 reported clinical trials
16 drugs studied
Clinical Trials running at University of Michigan - Brighton Center for Specialty Care
Breast Cancer
Squamous Cell Carcinoma
Gallbladder Cancer
Cancer
Prostate Cancer
Oropharyngeal Carcinoma
Small Intestinal Adenocarcinoma
Pancreatic Cancer
Anal Cancer
Ovarian Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Michigan - Brighton Center for Specialty Care?
University of Michigan - Brighton Center for Specialty Care is a medical facility located in Brighton, Michigan. This center is recognized for care of Cancer, Squamous Cell Carcinoma, Adenocarcinoma, Tumors, Bladder Cancer and other specialties. University of Michigan - Brighton Center for Specialty Care is involved with conducting 24 clinical trials across 158 conditions. There are 13 research doctors associated with this hospital, such as Francis P. Worden, Zachery R. Reichert, Jean H. Siedel, and Mark M. Zalupski.